CS Paper Radar

AI-based characterization of lymphoid structures and the tumor microenvironment reveals lower mature tertiary lymphoid structures, lymph-node follicles, and plasma cells after neoadjuvant therapy in lung squamous cell carcinoma

Arne Schmidt, Justin Nieder, Cornelius Boehm, Julika Ribbat-Idel, Marius Teodorescu, Marie-Lisa Eich, Simon Schallenberg, Gabriel Dernbach, Katja Lingelbach, Miriam Haegele, Timo Milbich, Adam Narai, Maria Stoelben, Hans Pinckaers, Lukas Ruff, Kai Standvoss, Christian Watermann, Christiane Kuempers, Sven Perner, Verena Sailer, Jasmin Tiebach, Torsten Goldmann, Sebastian Marwitz, Johannes Braegelmann, Frederick Klauschen, Marija Pezer, Rosemarie Krupar

cs.CV q-bio.QM ·submitted 2026-11-09 18:45 UTC · v1

Abstract

Mature, germinal centre-bearing tertiary lymphoid structures (TLS) and mature lymph node follicles (secondary lymphoid structures, SLS) sustain the plasma cell response that shapes outcome and immunotherapy benefit in lung cancer. How this loco-regional axis differs between neoadjuvant-treated and therapy-naive tumors is poorly defined. We analyzed H&E whole-slide images of resected tumors and paired proximal and distal lymph nodes from matched neoadjuvant-treated (neoLUSC, n=20) and therapy-naive (naivLUSC, n=20) lung squamous cell carcinoma (LUSC) patients. Aignostics Atlas H&E Tissue Analysis (HETA) models quantified cell densities per tissue compartment and cell-cell co-localization; a dedicated deep-learning model validated against pathologist annotations detected TLS and SLS and graded their maturity. Prognostic value was tested in an independent cohort (n=458; 46 treated). In neoLUSC tumors, stromal plasma cell density was 72% (p=0.004) and stromal lymphocyte density 48% (p=0.015) lower than in naivLUSC; macrophages and granulocytes did not differ significantly. Total and immature TLS did not differ, whereas mature TLS in the tumor (p=0.034) and mature SLS in the tumor-distal lymph node (p=0.003) were lower in neoLUSC patients. Peri-TLS plasma cell density correlated with tumor lymphocyte density in naivLUSC (rho=0.54, p=0.017) but not in neoLUSC tumors (rho=0.07). In the validation cohort, stromal plasma cell density (HR 0.69, p=0.011) and lymphocyte-plasma cell co-localization (HR 0.66, p=0.004) were associated with longer survival, and neoadjuvant status with shorter survival (HR 1.50, p=0.026). Neoadjuvant therapy is thus associated with fewer mature lymphoid structures and weaker coupling of the humoral compartment to the tumor rather than uniformly lower immune readouts. The stromal plasma cell/co-localization axis is a candidate prognostic biomarker.

Closest papers

Nearest neighbours by meaning across the whole index.

Automated PD-L1 Tumor Proportion Scoring with Uncertainty-Guided Triage in Non-Small Cell Lung Cancer

cs.CV eess.IV ·2026-11-12 ·Kesi Xu, Ayesha Azam, Tanvier Kaur, Monika Kondratowicz, Kinza Asim +5 more
hot direction similarity 0.63
Abstract · 55 pages (29-page main text with 5 figures and 3 tables, followed by 26 pages of supplementary material)

Programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) informs immunotherapy selection in non-small cell lung cancer. Near the 1% and 50% cutoffs, the score should also indicate when closer review is warranted. We designed a three-stage framework to follow the sequence of TPS assessment. Stage 1 identifies tumor regions and excludes macrophage-rich patches. Stage 2, a dual-branch cell counting network (D2Count-Net), counts PD-L1-positive and PD-L1-negative tumor cells in these regions to calculate TPS. Stage 3, TPS-Guard, an uncertainty-guided triage mechanism, reports model uncertainty as the disagreement among independently trained models, refers the most uncertain slides, and flags scores near the 1% or 50% cutoff when model estimates disagree across that cutoff. Flags state the reason for referral or alert the pathologist to possible scoring errors on auto-reported slides. In a retrospective, single-center study, 154 whole-slide images were scored by three pathologists, and the model and each pathologist were compared in turn with the mean of the other two. On the 114 slides unseen in training, model mean absolute error (MAE) was 6.96 percentage points, within the range of the three pathologists (4.24 to 8.29), and model uncertainty correlated with absolute TPS error (Spearman rho = 0.77) and inter-pathologist disagreement (rho = 0.71). After referral of the 15% most uncertain slides, model and pathologist MAE both decreased. Applied without retraining to an external, publicly available dataset, TPS-Guard still directed review to higher-error cases, and referring more uncertain cases raised sensitivity at the 50% cutoff. TPS-Guard provides reasons for reviewing individual automated scores and identifies slides that also produce greater disagreement among pathologists. Prospective reader studies should assess TPS-Guard's effect on TPS reporting.

0.32

HEmIF-Bench: Benchmarking H&E-to-mIF Models BeyondVirtual-StainFidelity

cs.CV ·2026-11-15 ·Fuxian Zhao, Hyokeun Park
benchmark similarity 0.61
Abstract · 11 pages, 3 figures, 2 tables

Hematoxylin and eosin (H&E)-to-multiplex immunofluorescence (mIF) generators predict spatial protein expression from routine histology, yet pixel-level marker reconstruction does not establish downstream utility. We present HEmIF-Bench, evaluating five frozen generators across eight datasets spanning molecular, cellular, tissue, and patient scales. HEmIF-Bench decouples internal encoder features from generated outputs, benchmarking both against the pathology foundation reference UNI2. Mirroring the clinical workflow where pathologists rely on mIF to define cell phenotypes, delineate tertiary lymphoid structures (TLSs) and germinal centers (GCs), and stratify patient risk, we evaluate external CD3 recovery, single-cell classification, dense nuclear segmentation, TLS/GC segmentation, and patient survival prediction. Across the benchmark, foundation-model-based MIPHEI-ViT leads among the generators, while non-foundation models show task-specific strengths. Comparing the two routes reveals that internal encoder features generally outperform generated outputs, and larger output marker panels do not guarantee stronger downstream utility across datasets. Moreover, neither internal encoder features nor generated outputs consistently surpass frozen UNI2. These findings show that pixel-level stain fidelity does not equate to downstream utility, and that generators trained at current paired-data scales have yet to surpass large-scale pure-H&E foundation models. With the expansion of paired translation cohorts and the advancement of foundation-based generative architectures, HEmIF-Bench establishes a definitive benchmark for tracking when H&E-to-mIF generation crosses the threshold to deliver genuine value beyond routine histology for tumor microenvironment analysis and precision oncology.

0.13

Conserved Immune Topology Improves Pathology Foundation Model Generalization for Cross-Cancer MSI-H Prediction

cs.CV ·2026-09-04 ·Dasari Naga Raju
published similarity 0.61
Abstract · Accepted at the ECCV 2026 Workshop on Medical Foundation Models and Benchmarks (MedFM-Bench). 15 pages, 2 figures

Pathology foundation models integrated with multiple instance learning achieve competitive accuracy within single-cancer cohorts, yet cross-cancer generalization remains unresolved due to organ-specific histological and architectural differences. In this paper, we propose Conserved Immune Topology (CIT), a lightweight spatial representation for cross-cancer MSI-H prediction that augments foundation-model embeddings with biologically motivated immune descriptors. CIT uses unsupervised clustering to identify immune-associated tiles, then encodes tertiary lymphoid structures, peritumoral immune reactions, multi-scale tumor-infiltrating lymphocyte density, and immune-tumor mixing from frozen foundation-model embeddings and tile coordinates without requiring annotations or target-domain data. The proposed method was evaluated under cross-site and cross-cancer settings using CPTAC-COAD and TCGA-STAD cohorts, which introduce scanner variability, distribution shifts, and organ-specific architectural variations. Zero-shot cross-cancer transfer with CIT increased TransMIL AUC from 0.6627 to 0.7161, an absolute gain of 0.0534 (p=0.003), with consistent improvements across all three MIL aggregators. These results suggest that spatial immune topology provides potentially an organ-invariant representation for MSI-H prediction, supporting cross-cancer generalization of pathology foundation models.

0.34

Deep Learning for Automated Quantification of Tumor-Associated Macrophages from H&E-Stained Slides in Diffuse Large B-Cell Lymphoma

eess.IV ·2026-08-19 ·Anastasiia Studenikina, Svetlana Illarionova, Joaquim Carreras, Daniil Sulimov, Olga Filimonova +5 more
similarity 0.61
Abstract · 17 pages, 5 figures, 7 tables

While M2-polarized tumor-associated macrophages (TAMs) have been established as indicators of disease aggressiveness in diffuse large B-cell lymphoma (DLBCL), traditional CD163 immunohistochemistry (IHC) remains resource-intensive. This study aims to investigate the feasibility of using deep learning to quantify TAMs directly from standard hematoxylin and eosin-stained (HE) tissue sections. Using a curated dataset of 52 patients with DLBCL, with high-resolution HE images and IHC-validated annotations (1,713 TAM instances), five architectures were evaluated: U-Net, Swin-U-Net, Cerberus-U-Net3+, YOLOv11, and HoVer-Net. High CD163 TAM density (>20.04%) was associated with significantly reduced overall survival (HR 2.73; 95% CI:1.21-6.16; p=0.012) and progression-free survival (HR 2.88; 95% CI: 1.23-6.76; p=0.011). In multivariate Cox proportional hazards analysis adjusting for IPI, molecular subtype (GCB/non-GCB per Hans algorithm), EBV status, and age, CD163 TAM density showed a prognostic trend for overall survival (HR 3.24; 95% CI: 0.94-11.15; p=0.062) and progression-free survival (HR 2.41; 95% CI: 0.80-7.32; p=0.120). Among the evaluated models, the domain-specific Cerberus-U-Net3+ achieved the highest sensitivity (Recall 0.656), while the Transformer-based Swin-U-Net demonstrated superior segmentation fidelity (Precision 0.694, F1-score 0.633). Additionally, the survival analysis based on the predicted Swin-U-Net CD163 level revealed a 20.8% cutoff point for patients with high and low CD163 levels near IHC, as well as a downward trend in overall survival among patients with higher predicted CD163 values of 2.63 (95% CI: 0.85-8.33; p=0.083). These findings suggest that deep learning architectures using shifted-window self-attention show potential as a candidate surrogate for IHC that is scalable and cost-effective for prognostic assessment of TAMs in DLBCL.

0.22

Comprehensive Benchmarking of Deep Learning Architectures for Lung Cancer Histopathology

cs.CV cs.AI ·2026-08-16 ·Hadi Hasan, Safaa Salman, Lama Sleem, Ralph Mouawad, Ali Chehab
benchmark similarity 0.59
Abstract · 8 pages

Lung cancer remains the leading cause of cancer-related mortality worldwide, while histopathological diagnosis is often affected by inter-observer variability and the substantial workload associated with manual slide examination. Although deep learning has shown considerable potential in computational pathology, comprehensive benchmarks that integrate tissue classification and region segmentation within a unified analytical framework remain limited. This study presents a two-stage deep learning framework for multi-class tissue classification and pixel-level histopathological region segmentation, accompanied by a systematic comparison of state-of-the-art architectures at each stage. For tissue classification, six models, a custom convolutional neural network, VGG16, DenseNet, MobileNetV3, a custom Vision Transformer, and YOLO11, are evaluated on a combined dataset of 39,000 images derived from LC25000 and LungHist700. The models distinguish between adenocarcinoma, squamous cell carcinoma, and normal lung tissue. YOLO11 achieves the best classification performance, with an accuracy of 98.38%, a five-fold cross-validation accuracy of 98.21 +/- 0.35%, and a macro F1-score of 0.98. For region segmentation, U-Net, ResNet-encoder U-Net, DeepLabV3+, and YOLO11-seg are evaluated using the GlaS gland segmentation benchmark. DeepLabV3+ obtains the highest Intersection over Union of 0.80 and a Dice score of 0.89, while YOLO11-seg achieves a comparable Intersection over Union of 0.79 using approximately 14x fewer parameters. The best-performing classification and segmentation models are subsequently integrated into an end-to-end framework, providing an accurate, computationally efficient, and reproducible baseline for automated histopathological image analysis.

0.40

LUCAID: Agentic Multimodal AI for Lung Cancer Precision Pathology

cs.CV cs.AIcs.LG ·2026-08-24 ·Marie-Lisa Eich, Kai Standvoss, Timo Milbich, Alexander Möllers, Miriam Hägele +28 more
similarity 0.56
Abstract

Lung cancer tissue diagnostics is complex, as therapy decisions in precision oncology rely on the integration of histomorphological, immunohistochemical, and molecular features. Yet pathological assessment remains largely visual and semi-quantitative and shows interobserver variability, while existing artificial intelligence (AI) tools cover only selected tasks, rarely reach generalizable expert-level performance, and lack prospective clinical validation. To address these challenges, we developed and clinically validated LUCAID, an agentic AI system for precision lung cancer pathology. An integrative agent couples diagnostic reasoning with nine modules that cover the full routine workflow, from quality control, tumor detection and segmentation, histological subtyping, tumor microenvironment profiling, tumor cellularity quantification, and predictive biomarker scoring (PD-L1, MET, TROP-2) to automated structured report generation. LUCAID enables users to interactively query the module outputs and generate reports that contextualize the results. Against large-scale expert ground-truth annotations, the analysis modules achieved F1 scores of 0.82-0.95. In prospective clinical validation, LUCAID reached 93.0% concordance with an expert-panel adjudicated reference standard across clinically actionable decisions, compared with 68.3-81.1% for five experienced thoracic pathologists.

0.26

CellPath-Bench: A Multidimensional Benchmark for Whole-Slide Cellular Representations in Pathology Foundation Models

cs.AI cs.CV ·2026-08-21 ·Bokai Zhao, Yiyang Zhang, Hanqing Chao, Yawei Ma, Long Bai +4 more
benchmark similarity 0.54
Abstract

Pathology foundation models (PFMs) are increasingly used as general-purpose backbones, yet existing benchmarks cannot systematically diagnose their whole-slide cellular representation capabilities, including the decodability of cell-type information and the transferability of such information across tissue sections, datasets, and anatomical organs. We introduce CellPath-Bench, a cellular-resolution benchmark that evaluates frozen PFMs themselves. Following quality control of 52 candidate Xenium datasets, we construct a panel of 25 spatially aligned H\&E--Xenium tissue sections spanning 11 organs and 7,079,283 cells, harmonized into fine- and coarse-grained taxonomies. CellPath-Bench samples frozen WSI feature maps at registered nuclear coordinates and evaluates them using standardized multiclass linear probes. Cell Representation Advantage (CRA) measures the within-section advantage of nucleus-anchored representations over patch-level mean pooling, while Cell Representation Transferability (CRT) characterizes the generalization of cell-type decodability across tissue sections, datasets, and organs. We benchmark 30 pathology-specific and general-purpose foundation models through 304,920 runs across spatial readouts, magnifications, taxonomic granularities, and evaluation protocols. The results reveal substantial model-dependent differences in cell-type decodability and its cross-domain generalization, yielding distinct multidimensional capability profiles. CellPath-Bench provides a standardized framework for auditing cellular information in frozen PFM representations.

0.15

Can Unsupervised Methods Outperform Supervised Deep Learning When Ground Truth Is Sparse? A Case Study of Bronchovascular Bundle Segmentation in Low-Dose CT

cs.CV ·2026-08-17 ·Anna Mrukwa, Marek Socha, Aleksandra Suwalska, Agata Durawa, Malgorzata Jelitto +7 more
similarity 0.54
Abstract · 17 pages, 4 figures. Part of this research was submitted to the international conference European Molecular Imaging Meeting 2026

Background Lung cancer remains the deadliest cancer worldwide because it is often diagnosed too late. Effective treatment depends on detection at an early screening stage. However, the growing number of patients and the limited number of radiologists lead to prolonged diagnostic waiting times. In very early stage lung cancer, nodule visibility is further reduced by adjacent blood vessels and airway walls, because nodules are often connected to or supplied by these structures. Task-specific analysis of the bronchovascular bundle is therefore important for efficient nodule detection, and its removal can increase the diagnostic potential of lung cancer screening. Materials and Methods To assess the efficacy of the proposed method, we used series from widely utilized LDCT datasets, including the Duke Lung Cancer Screening (DLCS) dataset and the Pilot Pomeranian Lung Cancer Screening Program. The proposed bronchovascular bundle segmentation pipeline, RONALD, operates on computed tomography images and returns binary masks of vessels and bronchi located in the lung parenchyma. The method includes a preprocessing stage with lung, lobe, and mediastinum segmentation, followed by separate vessel and bronchial tree segmentation. Results The proposed pipeline segmented the bronchovascular bundle in low-dose computed tomography scans while improving nodule retention compared with other segmentation methods: from 93.98% and 90.36% to 100% in DLCS, and from 83.16% and 62.36% to 99.92% in the Pomeranian dataset. Conclusion The resulting segmentations can improve lung nodule detection in the very early stages of lung cancer.

0.12